KLK3 and prostate carcinoma: [2] There is less variation in mortality rates worldwide (10-fold) than is observed for incidence, because PSA testing has a much greater effect on incidence than on mortality, and the number of deaths from prostate cancer is almost the same in developed and developing regions.